PTGS2-899G > C and prostate cancer risk: A population-based nested case-control study (ProtecT) and a systematic review with meta-analysis

Prostaglandin endoperoxidase synthase 2 is a key regulator of inflammation and may play a role in prostate carcinogenesis. The polymorphism, -899G > C (rs20417), alters a transcription factor-binding site and is associated with a reduced risk of colorectal adenoma. We tested the hypothesis that rs20417 may influence prostate cancer risk, using a large case-control study (n_cases = 1608, n_controls = 3058). We found no evidence that rs20417 alters prostate cancer risk (odds ratio (OR_{CC & GC v GG} = 1.05, 95% confidence interval (CI) = 0.91-1.20). A meta-analysis of three studies also found little evidence that rs20417 alters risk (pooled OR_{CC & GC v GG} = 1.04, 95% CI = 0.93-1.17), making it unlikely that rs20417 contributes in any major way to prostate cancer aetiology.